Skip to main content
OpenTrials
Completed

NCT Number: NCT00395148

Improving Metabolism With HDL Cholesterol

High levels of good cholesterol (HDL) in our blood decreases our chance of having a heart attack. This relates in part to the role good cholesterol plays in reducing build up of fat in the arteries. However, good cholesterol has many other protective effects. We have recently identified three enzymes (proteins) activated by HDL in cells lining the blood vessels, which may be responsible for some of HDL's protective actions.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Alfred Hospital

Melbourne, Victoria, 3004, Australia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18 - 65 years
  • Free of overt coronary disease
  • Body mass index <35 kg.m-2
  • Fasting plasma glucose > 7 mmol/L-1
  • No major illness

Exclusion criteria

  • Unable to give informed consent
  • Smokers
  • Abnormal LFT, U&E, FBE or creatinine

Treatment and study plan

rHDL

Drug

Primary outcomes

  1. Metabolic parameters

Sponsors and collaborators

Lead sponsor

Bayside Health

Other Gov

Collaborators

  • Baker Heart Research Institute

Registry information

Official study title

A Novel Mechanism Mediating Anti-atherosclerotic and Metabolic Actions of HDL Cholesterol

Important dates

Study start
2006
Primary completion
2008
Study completion
2008
First posted
Nov 2, 2006
Registry last updated
May 10, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.